Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.

摘要: Denosumab and zoledronic acid are potent antiresorptives. In this study in patients pre-treated with acid, denosumab achieved similar increases lumbar spine BMD despite the more prominent reduction of bone turnover markers. reversibly reduced endogenous RANKL. We aimed to compare yearly changes (LS) mineral density (BMD), markers, free soluble receptor activator nuclear factor kappaB ligand (sRANKL) sclerostin levels between acid. Postmenopausal women low mass previously treated for 1 year were assigned injection (n = 32) or infusion (n = 26). Procollagen type 1 N-terminal propeptide (P1NP), C-terminal cross-linking telopeptide collagen (CTx), sRANKL, measured serum samples obtained at baseline 3, 6, 12 months after infusion. LS was 12 months. The mean increase 4.5 4.4 % respectively (p = 0.560). caused a larger decrease CTx 3 months (p < 0.001) P1NP 3 (p < 0.001), 6 (p = 0.021), (p = 0.042). significantly decreased sRANKL by 87.4 % (p < 0.001). Sclerostin not changed either intervention (p = 0.162 p = 0.214, respectively). reduces than but comparable. Furthermore, administration results reversible inhibition metabolically significant RANKL levels. Serum is affected agent.